Amorcyte receives patent for chemotactic hematopoietic stem cell product

Published on September 13, 2010 at 7:08 AM · No Comments

Amorcyte, Inc. (Amorcyte), a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair."  The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.  This is the first instance of a U.S. patent being issued for a chemotactic hematopoietic stem cell product, its delivery and the cell potency and stability needed to treat the consequences of a vascular injury.

Claims of this patent, which will remain in effect until at least May 2028, cover Amorcyte's proprietary formulation that maintains the potency of CD34+ stem cells having CXCR-4+ receptors and their ability to migrate quickly after delivery to the vascular injury site, as well as methods of delivering the product through use of a catheter.

"The issuance of this patent is a significant milestone for Amorcyte and provides us with a strong commercial position for our lead product candidate, AMR-001 to treat heart damage after an AMI, as well as other therapeutic indications in treating the consequences of vascular injury," said Andrew L. Pecora, M.D., Founder and Chairman of the Board of Amorcyte. "Understanding how fundamental this patent is to the emerging field of regenerative medicine, it is our desire to enter into appropriate collaborations with other companies whose development efforts complement our approach."  

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Finnish | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment